Biohaven, SK Biopharmaceuticals Sign Licensing Agreement for Epilepsy Drug

MT Newswires Live15:58

Biuohaven (BHVN) and SK Biopharmaceuticals said Wednesday that they have reached a licensing and collaboration agreement for an investigational focal epilepsy treatment.

SK Biopharmaceuticals will gain exclusive global rights to the treatment and take over all future program costs, the companies said.

The agreement includes $350 million payable at closing and a $50 million payment due in 2027, along with $150 million in potential regulatory milestones, alongside tiered royalties on net sales.

The acquiring partner will assume $245 million in specific financial obligations tied to the drug platform.

Shares of Biohaven were up nearly 10% in Wednesday premarket activity.

Price: 15.81, Change: +1.43, Percent Change: +9.94

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2662955967?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-26 15:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662955967","market":"fut","top_or_hot":-1,"title":"Biohaven, SK Biopharmaceuticals Sign Licensing Agreement for Epilepsy Drug","media":"MT Newswires Live","content":"<html><body><p> Biuohaven (BHVN) and SK Biopharmaceuticals said Wednesday that they have reached a licensing and collaboration agreement for an investigational focal epilepsy treatment.</p><p>SK Biopharmaceuticals will gain exclusive global rights to the treatment and take over all future program costs, the companies said.</p><p>The agreement includes $350 million payable at closing and a $50 million payment due in 2027, along with $150 million in potential regulatory milestones, alongside tiered royalties on net sales.</p><p>The acquiring partner will assume $245 million in specific financial obligations tied to the drug platform.</p><p>Shares of Biohaven were up nearly 10% in Wednesday premarket activity.</p><p>Price: 15.81, Change: +1.43, Percent Change: +9.94</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven, SK Biopharmaceuticals Sign Licensing Agreement for Epilepsy Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven, SK Biopharmaceuticals Sign Licensing Agreement for Epilepsy Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-26 15:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biuohaven (BHVN) and SK Biopharmaceuticals said Wednesday that they have reached a licensing and collaboration agreement for an investigational focal epilepsy treatment.</p><p>SK Biopharmaceuticals will gain exclusive global rights to the treatment and take over all future program costs, the companies said.</p><p>The agreement includes $350 million payable at closing and a $50 million payment due in 2027, along with $150 million in potential regulatory milestones, alongside tiered royalties on net sales.</p><p>The acquiring partner will assume $245 million in specific financial obligations tied to the drug platform.</p><p>Shares of Biohaven were up nearly 10% in Wednesday premarket activity.</p><p>Price: 15.81, Change: +1.43, Percent Change: +9.94</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SK","symbol_name":"2倍做多海力士ETF-Corgi","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2662955967","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662955967","pubTimestamp":1787731123,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biuohaven  and SK Biopharmaceuticals said Wednesday that they have reached a licensing and collaboration agreement for an investigational focal epilepsy treatment.SK Biopharmaceuticals will gain exclusive global rights to the treatment and take over all future program costs, the companies said.The agreement includes $350 million payable at closing and a $50 million payment due in 2027, along with $150 million in potential regulatory milestones, alongside tiered royalties on net sales.The acquiring partner will assume $245 million in specific financial obligations tied to the drug platform.Shares of Biohaven were up nearly 10% in Wednesday premarket activity.Price: 15.81, Change: +1.43, Percent Change: +9.94","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SK":"2倍做多海力士ETF-Corgi"},"translate_title":"Biohaven 与 SK Biopharmaceuticals 签署癫痫药物许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SK":1.5},"content_text":"Biuohaven (BHVN) and SK Biopharmaceuticals said Wednesday that they have reached a licensing and collaboration agreement for an investigational focal epilepsy treatment.SK Biopharmaceuticals will gain exclusive global rights to the treatment and take over all future program costs, the companies said.The agreement includes $350 million payable at closing and a $50 million payment due in 2027, along with $150 million in potential regulatory milestones, alongside tiered royalties on net sales.The acquiring partner will assume $245 million in specific financial obligations tied to the drug platform.Shares of Biohaven were up nearly 10% in Wednesday premarket activity.Price: 15.81, Change: +1.43, Percent Change: +9.94","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2662955967","isCrawlerRequest":true}